ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01514812
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 46
- Registration Number
- NCT01514838
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 128
- Registration Number
- NCT01511003
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 171
- Registration Number
- NCT01505426
Drug Interaction Study of Isavuconazole and Cyclosporine
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01494597
- Locations
- 🇺🇸
Covance, Madison, Wisconsin, United States
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01489696
- Locations
- 🇬🇧
Covance CRU Ltd, Leeds, United Kingdom
Post Marketing Survey of Vesicare in Japan
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1160
- Registration Number
- NCT01489709
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01486017
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01484964
- Locations
- 🇺🇸
PAREXEL, Glendale, California, United States
To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478490
- Locations
- 🇳🇱
PRA International (former Pharma Bio-Research), Zuidlaren, Netherlands
© Copyright 2024. All Rights Reserved by MedPath